Development of a combined vaccine against equine influenza and tetanus. Experiment outside containment (clinical trial) for the study of the safety and efficacy of an intramuscular administration of recombinant canarypoxvirus expressing equine influenza v

EU record number

B/BE/00/V15

Company / Sponsor

Merial

Treated organism

Horses

Indication category

vaccination against equine influenza virus

Genetic modification

haemagglutinin gene from equine influenza virus A2/Kentucky/94 or equine influenza virus A2/Newmarket/2/93

Method of transfer of nucleic acid of interest

Canarypoxvirus (ALVAC clone)

Route of administration

Intramuscular

Locations in Belgium

Gentbrugge and Bornem

Nr of subjects

50

Foreseen duration

12 months

Type of procedure

Deliberate release only

Information for the public

Information related to the decision procedure

14 March: The Federal Public Service Health, Food chain safety and Environment gives a final decision (positive with conditions) for this trial.

© Sciensano - Version 1.0 (20260902.1)